Product Document Searching Made Easy by 2D Code! | TCI Chemistry News July 2026 | [Product Highlights] Chain Transfer Agents for Cationic RAFT... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 190791-29-8 | 產品號碼: L0336
Lasofoxifene Tartrate
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| NMR | confirm to structure |
性質
| 熔點 | 185 °C(dec.) |
GHS
相關法規
| RTECS # | QK4252964 |
運輸資料
| HS編碼* | 2933.99-000 |
Application
Lasofoxifene tartrate: A Third-Generation, Non-Steroidal Selective Estrogen Receptor Modulator (SERM)
Lasofoxifene tartrate (CP-336156) is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). SERMs have the ability to provide mixed functional estrogen receptor (ER) agonist or antagonist activity, depending on the target tissue. Lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs, selectively binds to both ERα and ERβ with high affinity, and acts as a tissue selective estrogen antagonist or agonist.1-3) It has been reported that lasofoxifene prevents estrogen deficiency-induced bone loss, inhibits breast tumor formation and reduces serum cholesterol. In clinical, lasofoxifene tartrate has been used for the treatment of osteoporosis4) and breast cancer.5,6) (The product is for research purpose only.)
References
- 1) Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
- 2) Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene
- 3) Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat
- 4) Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis (a review)
- 5) Preventive therapy for breast cancer: a consensus statement (a review)
- 6) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice (a review)
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
請輸入TCI產品號碼
text.certificate.product.input.placeholder.kishida
4或5個單字節字母數字字符
text.certificate.lotno.input.placeholder.kishida
SDS
產品規格
沒有搜索到 產品規格。
如需更多幫助，請 聯繫我們 。
text.specification.search.errormsg.content.1.kishida
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
• 請確認您輸入的批號。
• 如果您輸入的信息無誤，請 聯繫我們 。
• text.certificate.analysis.pdf.errormsg.content6.kishida
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
很抱歉，您搜索的分析圖譜無法提供。